The DES Landscape in 2011
|
|
- Cuthbert Garrett
- 5 years ago
- Views:
Transcription
1 The DES Landscape in 2011 Future directions in drug-eluting stent design. BY JEFFREY S. KUNZ, MD, AND MARK A. TURCO, MD, FACC, FSCAI The development of bare-metal stents (BMS) in the late 1980s revolutionized the treatment of elastic recoil and reduced the risk of acute vessel closure that complicated plain old balloon angioplasty. 1,2 The development of neointimal hyperplasia associated with the use of the BMS led to in-stent restenosis rates of 20% to 30%, prompting an increase in repeat revascularization rates and, ultimately, the development of the first drug-eluting stent (DES) in Despite studies showing consistent reductions in target lesion revascularization (TLR) rates with current-generation DES platforms, stent thrombosis (ST) continues to remain a rare but potentially devastating clinical consequence that is associated with significant morbidity and mortality. 3 Although studies have shown no difference in the rates of early (< 30 days) and late (1 month to 1 year) ST between BMS and DES designs, DES designs have been associated with higher rates of very late (> 1 year) ST Independent predictors of ST include premature cessation of dual-antiplatelet therapy (DAPT), as well as lesionand procedure-related characteristics (ie, small vessels, lesion length > 28 mm, stent undersizing, dissection). 15,16 In addition, the permanent (durable) polymers associated with DES have been shown to delay endothelialization and cause hypersensitivity reactions that can culminate in ST Therefore, in an effort to minimize local vascular inflammation and hasten stent endothelialization and vascular healing, four new DES designs are being studied with the theoretical hope of reducing late ST as well as the duration of DAPT. These designs include durable polymers on new thinner strut platforms, resorbable polymers, nonpolymeric, and completely bioabsorbable DES designs. NOVEL METALLIC DURABLE POLYMER DESIGNS Several DES stent designs are under investigation that attempt to improve on the early-generation DES that are currently in use. These newer designs, which have already gained CE Mark approval in Europe, are still under evaluation in the United States by the Food and Drug Administration. The new designs use more biocompatible polymers and thinner, more radiopaque struts to enhance stent deliverability and angiographic visualization. These designs are summarized in Table 1. The Endeavor Resolute and Resolute Integrity zotarolimuseluting stents (ZES) (Medtronic, Inc., Minneapolis, MN) are currently undergoing evaluation in the United States and are commercially available outside the United States. These devices utilize a BioLinx polymer (combination of three different polymers: hydrophobic C10 polymer to control drug release, biocompatible and hydrophilic C19 polymer, and polyvinyl pyrrolidone to allow early drug release) mounted on a cobalt chromium stent platform (Driver [Medtronic, Inc.] or the Integrity stent). 22 The 139-patient, multicenter, nonrandomized, first-inman RESOLUTE trial revealed an angiographic in-stent late loss of 0.22 mm at 9 months of follow-up. Major adverse cardiac events (MACE), TLR, and any definite/probable ST were 8.6%, 0.7%, and 0%, respectively, at 12-month follow-up, with similar low rates of TLR and no ST reported out to 4 years of follow-up The Resolute stent was then evaluated in the randomized 2,300-patient RESOLUTE All-Comers noninferiority trial in which patients were randomized in a 1:1 fashion to either the Resolute ZES or the Xience V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, CA). The Resolute ZES was found to be noninferior to the EES at 12-month follow-up for the primary endpoint of target lesion failure (a composite of cardiac death, target vessel myocardial infarction, and clinically indicated TLR) (8.2% vs 8.3%; P noninferiority <.001). 26 In addition to novel polymer development, there have been new stent platform designs. The new Element stent platform (Boston Scientific Corporation, Natick, MA) is a 48 ICARDIAC INTERVENTIONS TODAYIJANUARY/FEBRUARY 2011
2 TABLE 1. NEW METALLIC STENT DESIGNS WITH DURABLE POLYMERS Stent Drug (Dosage) Stent Platform Strut/Polymer Thickness (µm) Endeavor Resolute Zotarolimus (10 µg/mm) Cobalt chromium 91/4.1 Taxus Element Paclitaxel (1 µg/mm 2 ) Platinum chromium 81/15 Promus Element Everolimus (1 µg/mm 2 ) Platinum chromium 81/6 platinum chromium alloy and is combined with both everolimus (Promus Element EES) and paclitaxel (Taxus Element paclitaxel-eluting stent [PES]). The platinum stent platform improves on cobalt chromium and stainless steel platforms through its much greater radiopacity and radial strength, allowing for better angiographic visualization and thinner stent struts. Furthermore, the reduced nickel content in the platinum alloy may possibly reduce the risk of hypersensitivity. 27,28 The noninferiority, 1,262-patient PERSEUS Workhorse trial randomized patients to treatment with the Taxus Element or the Taxus Express PES and revealed no significant differences in late loss (0.34 ± 0.55 mm vs 0.26 ± 0.52 mm; P =.33) between the two systems at 9 months of angiographic follow-up and no difference in the rate of the primary endpoint of target lesion failure at 12 months (5.6% vs 6.1%; P =.78), which together met the criteria for noninferiority. 29 The PERSEUS Small Vessel trial compared the Taxus Element with a BMS platform in 224 patients with lesions < 20 mm in length within vessels between 2.25 and 2.75 mm in diameter. At 9 months of follow-up, significantly lower in-stent late loss was seen with the Element stent compared with the BMS stent (0.38 ± 0.51 mm vs 0.8 ± 0.53 mm; P <.001), with significantly lower target lesion failure and MACE rates at 12 months favoring the Element stent. 30 The multicenter PLATINUM (A Prospective, Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [Promus Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) trial, randomizing 1,532 patients to either the Promus Element stent or the Promus EES, will be reported at the American College of Cardiology s 2011 Annual Scientific Session. 29,30 METALLIC RESORBABLE POLYMER DESIGNS Interest in resorbable polymer technology has emerged as a result of the ongoing concerns over very late ST that is speculated to result from the vascular inflammation and consequential delayed endothelialization associated with the polymers used in current DES designs. Theoretically, DES designs involving these resorbable polymers may offer the early benefits of reducing neointimal proliferation while reducing the risk of very late ST and the duration of DAPT. Numerous resorbable polymer DES designs are currently under investigation and represent the most robust area of novel DES research. Representative studies are summarized in Table 2. The Biomatrix (Biosensors International, Singapore) and Nobori (Terumo Europe NV, Leuven, Belgium) stents have a stainless steel stent platform that is combined with Biolimus A9, a lipophilic sirolimus analogue that is bound to the stent platform via a poly-l-lactide biodegradable polymer that biodegrades within 6 to 9 months. The Biomatrix stent design was compared with the Cypher SES (Cordis Corporation, Bridgewater, NJ) in the 1,707-patient, randomized, all-comers LEADERS trial and was shown to be noninferior for MACE (composite of cardiac death, myocardial infarction, and ischemiadriven revascularization) at both 12-month and 2-year follow-up. 31,32 The Nobori stent has been compared with the Cypher SES and Taxus PES in the NOBORI CORE and Nobori I studies. At 9-month follow-up, the Nobori stent was shown to be noninferior to the Cypher SES and superior to the Taxus PES with respect to late lumen loss (0.1 mm vs 0.12 mm; P =.66; 0.11 mm vs 0.32 mm; P =.001, respectively). 33,34 Encouragingly, the Nobori I study revealed a lower rate of ST at 9 months compared with the Taxus PES. 34 Furthermore, to date, no episodes of very late ST have been reported with the Nobori stent design. Consequently, these two stent designs have received CE Mark approval in Europe. In addition to Biolimus A9 stent designs, multiple sirolimus-based biodegradable polymeric stents are under investigation. The Supralimus stent (Sahajanand Medical Technologies Pvt. Ltd., Gujarat, India) is composed of a stainless steel sirolimus-eluting stent with a biodegradable polymer mix of poly-l-lactide, polyvinyl pyrrolidone, polylactide-co-caprolactone, and polylactide-co-glycolide. The sirolimus elution is complete within 48 days, and the polymer is completely degraded within 7 months. Clinical effectiveness and safety have been JANUARY/FEBRUARY 2011 I CARDIAC INTERVENTIONS TODAY I 49
3 TABLE 2. NEW METALLIC STENT DESIGNS WITH BIODEGRADABLE POLYMERS Stent Drug (Dosage) Stent Platform Strut/Polymer Thickness (µm) Polymer Type (Duration of Biodegradation, Months) Biomatrix Biolimus A9 (15.6 µg/mm) Stainless steel 112/10 Abluminal PLA (6 9) Nobori Biolimus A9 (15.6 µg/mm) Stainless steel 112/10 Abluminal PLA (6 9) Supralimus Sirolimus (125 µg/19 mm) Stainless steel 80/4 5 PLLA, PLGA, PLC, PVP (7) Excel Sirolimus ( µg/19 mm) Stainless steel 119/15 PLA (6 9) Nevo Sirolimus (166 µg/17 mm) Cobalt chromium 99 Reservoirs of PLGA (3) Synergy Everolimus (low dose, 56 µg/20 mm standard dose, 113 µg/20 mm) Platinum chromium Low dose, 71/3; standard dose, 4 PLGA rollcoat abluminal (3) Abbreviations: PLA, poly-l-lactide; PLC, 75/25 poly-l-lactide-co-caprolactone; PLGA, 50:50 poly-dl-lactide-co-glycolide; PLLA, poly-l-lactic acid; PVP, polyvinyl pyrrolidone. shown in the 100-patient SERIES I study that revealed a 0% in-stent restenosis rate, with a late loss of 0.09 ± 0.37 mm at 6-month follow-up. 35 In addition, the rate of target vessel revascularization was 4%, with no ST reported. Further evaluation is ongoing with the SERIES III noninferiority trial, which will look at a primary endpoint of 9-month in-stent late loss in patients randomized to the Supralimus SES versus Xience V EES. The Excel stent (JW Medical Systems, Weihai, China) is coated with sirolimus as well as a poly-l-lactic acid biodegradable polymer, which is completely degraded within 6 to 9 months. The CREATE (Multicenter Registry Trial of Excel Biodegradable Polymer Drug- Eluting Stent) registry of more than 2,000 patients has shown a MACE rate of 3.1% at 18 months of follow-up and an ST rate of 0.87% despite 80.5% of patients stopping clopidogrel at 6 months. 36 Finally, the Nevo stent (Cordis Corporation) has an open-cell, cobalt chromium design with a polylactideco-glycolide biodegradable polymer that elutes sirolimus within reservoirs rather than through a surface polymer coating. It has been evaluated in the RES- 1 (NEVO RES-ELUTION) study, which was a 394- patient, multicenter, randomized, noninferiority study comparing the Nevo stent to the Taxus Liberté PES (Boston Scientific Corporation). At 6 months, there was significant reduction of in-stent late lumen loss with the Nevo stent compared to the Taxus Liberté (0.13 mm vs 0.36 mm; P <.0001), with no difference in ST rates. 37 Further investigation is ongoing. The only everolimus-eluting biodegradable polymer stent platform being investigated is the Synergy stent (Boston Scientific Corporation). This polylactide-co-glycolide abluminal-coated biodegradable platform on an ultra-thin strutted stent ( inch) will be investigated in the 291-patient, multicenter EVOLVE trial. The EVOLVE trial will randomize patients to two doses of everolimus (113-µg/20-mm stent vs 56-µg/20-mm stent) delivered on an Element stent, with a Promus Element stent as the control. The primary angiographic endpoint is 6-month in-stent late loss, and the primary clinical endpoint is target lesion failure at 30 days. 38 METALLIC NONPOLYMERIC DESIGNS The ongoing search for stent designs that possess antiproliferative properties without delaying the reendothelialization process prompted the development of DES designs that were completely polymer-free. This is achieved through dissolving the antiproliferative agent into a biodegradable carrier on the stent s surface, impregnating the antiproliferative agent onto the porous surface of the stent or directly attaching the antiproliferative agent to the stent. This area of novel DES design is limited, with only one DES (Yukon stent [Translumina, Hechingen, Germany]) available for commercial use in Europe. However, there are several additional stents that are undergoing study, which are summarized in Table 3. The Yukon DES has a microporous structure in which the antiproliferative agent (rapamycin) is deposited, eliminating the need for a polymer. The stent system allows for a point-of-care stent coating via a two-component system: the premounted stent in a disposable coating cartridge and a coating device. The Yukon stent has been evaluated in more than 400 patients in both the randomized ISAR TEST study and a real-world registry, which collectively reveal noninferiority of the Yukon stent compared with a PES at 9- and 12-month follow-up. 39,40 In addition, recent data reveal a significantly lower change 50 ICARDIAC INTERVENTIONS TODAYIJANUARY/FEBRUARY 2011
4 TABLE 3. NEW METALLIC NONPOLYMERIC STENT DESIGNS Stent Drug (Dosage) Stent Platform Strut/Coating Thickness (µm) Yukon Sirolimus ( µg) Stainless steel 87 BioFreedom Biolimus A9 (standard dose, 15.6 µg/mm; low dose, 7.8 µg/mm) Stainless steel 112 Vestasync Sirolimus (total = 55 µg) Stainless steel 65/0.6 Amazonia Pax Paclitaxel (2.5 µg/mm 2 ) Cobalt chromium 73/5 in late lumen loss out to 2 years of follow-up compared with SES and PES stents. 41 The BioFreedom (Biosensors International), Vestasync (MIV Therapeutics Inc., Vancouver, BC, Canada), and Amazonia Pax (Minvasys, Gennevilliers, France) stent designs are currently not approved for clinical use and continue to undergo clinical study. The BioFreedom stent is a 316L stainless steel, polymer-free stent coated with Biolimus A9. The first cohort of the first-in-man study of 75 low-risk patients with de novo coronary lesions who were randomized to either a standard-dose BioFreedom stent (15.6 µg/mm), low-dose BioFreedom stent (7.8 µg/mm), or a Taxus PES revealed no MACE or ST at 4-month followup in either study group and a significantly lower in-stent late loss with both BioFreedom stent arms compared with the Taxus PES (0.08 mm vs 0.12 mm vs 0.37 mm; P <.0001 and P =.002, respectively). 42 The Vestasync stainless steel stent has a surface coating that is a low dose of polymer-free sirolimus. It was evaluated in the 15-patient VESTASYNC I first-in-man clinical trial and showed reductions in in-stent late loss and intimal hyperplasia rate at up to 9 months, with only one reported clinical event (TLR) out to 3 years of follow-up. 43,44 Finally, the Amazonia Pax stent is a polymerfree stent composed of cobalt chromium that elutes paclitaxel. In the Pax A study of 30 patients who were randomized to either the Amazonia Pax stent or the Taxus PES, there was no significant difference in in-stent late lumen loss at 4 months and no deaths or ST in patients who were treated with the Amazonia Pax stent. 45 Further evaluation of this stent is ongoing in the 100-patient Pax B study. 46 BIODEGRADABLE DESIGNS The ability to percutaneously treat de novo coronary stenoses with a stent that provides the vessel wall support needed in the short-term to prevent elastic recoil and then completely biodegrade over time carries many advantages. Most notably, these advantages include the lack of triggers for ST, such as exposed stent struts or drug polymers, which, in turn, may reduce DAPT requirements. To date, the only drug-eluting biodegradable stent that is currently being evaluated in clinical trials is the everolimus-eluting bioresorbable vascular scaffold (Abbott Vascular). This device is composed of poly-l-lactic acid coated with a thin layer of a 1:1 mixture of an amorphous matrix of poly-d,l-lactide and 8.2 µg/mm of everolimus. Approximately 80% of the everolimus is eluted by 30 days, with the complete stent being fully absorbed within 2 years. This design was assessed in the 30-patient, prospective, multicenter, first-in-man ABSORB study. No ST was reported, and only one major adverse event (non Q-wave MI) was seen out to 3 years of follow-up In response to these results, the Abbott bioresorbable vascular scaffold received CE Mark approval in Europe in January 2011 and will be marketed under the brand name, Absorb. Studies are ongoing, including the multicenter, single-arm registry, ABSORB EXTEND. CONCLUSION Although the clinical efficacy of DES over BMS has been shown, newer generations of DES are under investigation. These newer-generation DES platforms aim to address concerns of safety and improved efficacy, as well as the longterm issues inherent to prolonged DAPT. Bioabsorbable polymers, polymer-free drug delivery, and fully bioabsorbable stents will attempt to minimize vascular injury and delayed stent endothelialization. Newer stent metals, such as platinum versus stainless steel and cobalt chromium, will be inherent to newer stent platforms. Additionally, there will be trends toward thinner-strut stent designs with new stent architectures, such as modular designs, and reservoir technology that endeavor to advance interventional treatment for coronary artery disease. JANUARY/FEBRUARY 2011 I CARDIAC INTERVENTIONS TODAY I 51
5 Jeffrey S. Kunz, MD, is a staff cardiologist at Walter Reed Army Medical Center in Washington, DC. He has disclosed that he holds no financial interest in any product or manufacturer mentioned herein. Dr. Kunz may be reached at (202) ; jeffrey.kunz@amedd.army.mil. Mark A. Turco, MD, FACC, FSCAI, is Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital in Takoma Park, Maryland. He has disclosed that he is a consultant to and speaker for Abbott Vascular, Boston Scientific Corporation, and Medtronic, Inc. Dr. Turco may be reached at (301) ; mturco@adventisthealthcare.com. 1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331: Fishman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331: Serruys PW, Daeman J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug eluting stents. Circulation. 2007;115: ; discussion Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and baremetal stents: a collaborative network meta-analysis. Lancet. 2007;370: Spaulding C, Daeman J, Boersma E, et al. A pooled analysis of data comparing sirolimuseluting stents with bare-metal stents. N Engl J Med. 2007;356: Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356: Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356: Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356: Roukoz H, Bavry AA, Sarkees ML, et al. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow up. Am J Med. 2009;122:158.e Daeman J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369: Wenaweser P, Daeman J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52: Onuma Y. Incidence of late stent thrombosis up to 5 years after implantation of drugeluting stents in clinical practice. Presented at: Meeting of the European Society of Cardiology; August 31, 2009: Barcelona, Spain. 13. Pinto Slottow TL, Steinberg DH, Roy PK, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol. 2008;102: James SK, Wallentin L, Lagerqvist B. The SCAAR-scare in perspective. EuroIntervention. 2009;5: Van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53: Lasala JM, Cox DA, Dobies D, et al. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv. 2009;2: Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48: Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52: Van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation. 1996;94: Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109: Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drugeluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47: Meredith IT, Worthley S, Whitbourn R, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007;3: Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation Resolute stent system, a prospective, multicenter, first-in-human trial. J Am Coll Cardiol Interv. 2009;2: Meredith IT, Worthley S, Whitbourn R, et al. Long term clinical outcomes with the next generation Resolute Stent System: a report of the 2-year follow up from RESOLUTE clinical trial. EuroIntervention. 2010;5: Meredith IT, Worthley S, Whitbourn R, et al. Four-year follow-up of a new zotarolimuseluting stent: results of the RESOLUTE first-in-man trial. Presented at: Transcatheter Cardiovascular Therapeutics 2010 scientific symposium; September 2010; Washington, DC. 26. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimuseluting coronary stents. N Engl J Med. 2010;363: Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial. Circulation. 2001;103: Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003;41: Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin strut: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol. 2010;56: Kereiakes DJ, Cannon LA, Feldman RL, et al. TAXUS PERSEUS: a novel platinum chromium, thin-strut TAXUS Element stent for the treatment of de novo coronary stenoses. Presented at: i2 Summit; March 15, 2010; Atlanta, Georgia. 31. Garg S, Sarno G, Serruys PW, et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention. 2010;6: Klauss V. LEADERS: two-year follow up from a prospective randomized trial of Biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimus-eluting stents with a durable polymer. Presented at: Transcatheter Cardiovascular Therapeutics annual meeting; September 22, 2009; San Francisco, California. 33. Ostojic M, Sagic D, Beleslin B, et al. First clinical comparison of Nobori Biolimus A9 eluting stents with Cypher sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention. 2008;3: Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9- eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-phase 2. Circ Cardiovasc Interv. 2009;2: Dani S, Kukreja N, Parikh P, et al. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow up results from the series I prospective study. EuroIntervention. 2008;4: Han Y, Jing Q, Xu B, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in real world practice: 18-month clinical and 9-month angiographic outcomes. J Am Coll Cardiol Interv. 2009;2: Abizaid A. The NEVO RES Elution I study: a randomized multicenter comparison of the NEVO reservoir-based Sirolimus eluting-stent with the Taxus Liberté Paclitaxel-eluting stent: first presentation of the 12-month outcome. Presented at: EuroPCR annual meeting; May 25-28, 2010; Paris, France. 38. Dawkins KD. The Element stent technology. Presented at: EuroPCR annual meeting; May 25-28, 2010; Paris, France. 39. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006;113: Ruef J, Storger H, Schwarz F, Haase J. Comparison of a polymer-free rapamycin-eluting stent (Yukon) with a polymer-based paclitaxel-eluting stent (Taxus) in real-world coronary artery lesions. Catheter Cardiovasc Interv. 2008;71: Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Interv. 2009;2: Grube E. BioFreedom first in man progress report. Presented at: Transcatheter Cardiovascular Therapeutics annual meeting; September 24, 2009; San Francisco, California. 43. Costa JR Jr, Abizaid A, Costa R, et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. J Am Coll Cardiol Interv. 2009;2: Abizaid A. The MIV Vestasync polymer-free sirolimus-eluting stent program (microporous hydroxyapatite surface). Presented at: Transcatheter Cardiovascular Therapeutics annual meeting; September 21, 2009; San Francisco, California. 45. Abizaid A. PAX A trial (Amazonia Pax versus Taxus Liberté): 4-month follow up: IVUS and optical coherence tomography evaluation. Presented at: EuroPCR annual meeting; May 25-28, 2010; Paris, France. 46. Fajadet J. The Minvasys Amazonia Pax and Nile Pax polymer free paclitaxel eluting stent program. Presented at: Transcatheter Cardiovascular Therapeutics annual meeting; September 21, 2009; San Francisco, California. 47. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371: Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373: Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-l-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007;69: Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010;6: ICARDIAC INTERVENTIONS TODAYIJANUARY/FEBRUARY 2011
NEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany Sousa J et al., JACC Cardioasv Interv 2010 10 years DES NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationAre New DES Designs Safer?
cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 56 Are New DES Designs Safer? Changes in stent platform, polymer, and drug components have led to improved outcomes. BY ASHWANI SASTRY, MD, AND MITCHELL W. KRUCOFF,
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationBiodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial
Clinical trial report Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial Biodegradable polymer drug-eluting stent (DES) platforms have the
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationBioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program
BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program T. Santoso Univ. of Indonesia Medical School Medistra Hospital Jakarta, Indonesia Biodegradable Abluminally Coated
More informationDoes the Metal Matter?
Does the Metal Matter? An overview of next-generation stent platforms. BY LOUIS A. CANNON, MD, FSCAI, FACC, FACP; GARY A. DANIEL, MD; KRISTIN L. HOOD, PHD; AND STEVEN J. YAKUBOV, MD, FACC Originally used
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationSCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationBioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationContinuing Cardiology Education
Continuing Cardiology Education Stent selection for percutaneous coronary intervention P. D. Williams* & M. Awan James Cook University Hospital, Middlesbrough, United Kingdom Keywords Coronary artery disease,
More informationChoice of drug-eluting stent evidence-based or empirical
Choice of drug-eluting stent evidence-based or empirical Upendra Kaul, MD DM FACC FAMS FSCAI* Aijaz H Mansoor, MD DNB (Cardiology)** ABSTRACT Percutaneous transluminal coronary angioplasty (PTCA) was developed
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationDevice and Clinical Program Highlights: SINOMED BuMA Stent
Device and Clinical Program Highlights: SINOMED BuMA Stent Runlin Gao, MD, FACC, FESC, FSCAI Fuwai Hospital, National Center for Cardiovascular Diseases, China CAMS, PUMC BuMA Supreme Platform and Pre-Clinical
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationPrimary Endpoint Results of the EVOLVE Trial
Journal of the American College of Cardiology Vol. 59, No. 15, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.016
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationInterventional Cardiology
For reprint orders, please contact: reprints@futuremedicine.com Interventional Cardiology Bioengineering stents with proactive biocompatibility Percutaneous coronary intervention has revolutionized the
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationNovel stent and drug elution technologies
REVIEW Novel stent and drug elution technologies To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationEberhard Grube MD FSCAI, FACC
SCAI 30 th Annual Scientific Sessions Orlando/Fla BMS and DES Thrombosis Differences among DES Eberhard Grube MD FSCAI, FACC HELIOS Heart Center Siegburg, Siegburg, Germany Stanford University, School
More informationYukon Choice PC Translumina trust is what counts
Sirolimus Eluting Coronary Stent System 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts DES with excellent long-term clinical outcome The Translumina PC drug-eluting
More informationBioabsorbable Scaffolds: The Next Holy Grail?
Bioabsorbable Scaffolds: The Next Holy Grail? New Cardiovascular Horizons New Orleans, LA June 06, 2013 Lewis B. Schwartz, M.D., F.A.C.S. Vascular Surgery and Endovascular Therapy University of Chicago
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationCONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE
CONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE Anwer Habib, 1 Hiroyoshi Mori, 2 Kazuyuki Yahagi, 2 *Aloke V. Finn 2,3 1. Parkview Heart Institute, Fort Wayne, Indiana, USA 2. CVPath Institute Inc.,
More informationZotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001
More informationReal world experience of GenXSync sirolimus eluting coronary stent system in patients with long coronary lesions: outcome of the GEL registry
International Journal of Advances in Medicine Hiremath MS et al. Int J Adv Med. 2016 Nov;3(4):1029-1033 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20163743
More informationStent Pipeline. The unquestionable benefits brought by drugeluting COVER STORY. An update on absorbable polymers and stents.
Stent Pipeline An update on absorbable polymers and stents. BY ALEXANDRE ABIZAID, MD, PHD; ANDRE LIMA BRITO, MD; AND J. RIBAMAR COSTA, JR, MD The unquestionable benefits brought by drugeluting stents (DES)
More informationNext Generation Drug- eluting Stent : Will It Solve the Problem?
Next Generation Drug- eluting Stent : Will It Solve the Problem? Yangsoo Jang, M.D., Ph.D, FACC Severance Cardiovascular Hospital Yonsei University Healthcare System Commercially Available DES An Epidemic
More informationDrug-Eluting Stents for Coronary Artery Disease: A Review
Dublin Institute of Technology ARROW@DIT Articles School of Mechanical and Design Engineering 2010 Drug-Eluting Stents for Coronary Artery Disease: A Review David Martin Dublin Institute of Technology,
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationThe introduction of drug-eluting stents (DES) led
Stent Thrombosis With Drug-Eluting Versus Bare-Metal Stents Changing trends in the evolution of DES technology. By Usman S. Khokhar, MD, and Allen Jeremias, MD, MSc The introduction of drug-eluting stents
More informationBiodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 19, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2016.03.475
More information3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
More informationXience V (Promus) Drug-Eluting Coronary Stent
Xience V (Promus) Drug-Eluting Coronary Stent Design features, preclinical data, and clinical outcomes. BY KRISHNA SUDHIR, MD, PHD, FRACP, FACC; DAVID R. RUTLEDGE, PHARM D, FAHA, FCCP; ALENA PECHONKINA,
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationCoroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems
Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative
More informationMID-TERM CLINICAL OUTCOMES OF ZOTAROLIMUS-ELUTING STENT IN PATIENTS WITH STABLE ANGINA PECTORIS
Pak Heart J ORIGINAL ARTICLE MID-TERM CLINICAL OUTCOMES OF ZOTAROLIMUS-ELUTING STENT IN PATIENTS WITH STABLE ANGINA PECTORIS 1 2 3 4 5 Yasir Adnan, Shahab Ud Din, Lubna Noor, Farooq Ahmad, Syed Tahir Shah,
More informationPercutaneous Coronary Intervention: an Update for the Internist
Percutaneous Coronary Intervention: an Update for the Internist Michael W. Cammarata, MD, MS Boca Raton Reginal Hospital Grand Rounds January, 9 2018 Objectives/Outline Background/Introduction Patient
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationLate-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 5, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.12.014 Late-Term Clinical
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More informationInterventional Cardiology
Interventional Cardiology s bare- An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use? Drug-eluting stents (DES) are recognized as
More informationInterventional Cardiology
n Interventional Cardiology Indigenous stents: examining the clinical data on new technologies The availability and utilization of percutaneous coronary intervention in developing countries is limited
More informationBIOFLOW V Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents
Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents David E Kandzari, MD; Laura Mauri, MD, MSc; Jacques Koolen, MD, PhD; Joseph M Massaro,
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationLATE AND VERY LATE STENT THROMBOSIS IN THE ERA OF SECOND-GENERATION DRUG-ELUTING STENTS
LATE AND VERY LATE STENT THROMBOSIS IN THE ERA OF SECOND-GENERATION DRUG-ELUTING STENTS Jaya Mallidi, *Amir Lotfi Division of Cardiology, Baystate Medical Center, Tufts University, Springfield, Massachusetts,
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationBioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens
Editorial Bioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens Athanasios Katsikis 1, Patrick W. Serruys 2 1 401 General Military Hospital of Athens, Cardiology Department,
More informationEmerging Cardiac Technologies. Thomas D. Conley, MD FACC FSCAI BHHI Primary Care Symposium February 27, 2015
Emerging Cardiac Technologies Thomas D. Conley, MD FACC FSCAI BHHI Primary Care Symposium February 27, 2015 None Financial Disclosures Examples of Emerging Technologies Therapeutic Bioabsorbable Stents
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
More informationCoronary Stents: Past, Present, Future
Coronary Stents: Past, Present, Future Michael C Kim, MD FACC Director Cath Lab and IC Lenox Hill Heart and Vascular Institute Northwell Health IC-296208-AN DEC 2016 Page 1 1st-Generation DES was not ideal
More informationDrug-eluting stents (DES)were primarily conceived to reduce
Advances in Interventional Cardiology New Drug-Eluting Stents An Overview on Biodegradable and Polymer-Free Next-Generation Stent Systems Alexandre Abizaid, MD, PhD; J. Ribamar Costa, Jr, MD Drug-eluting
More informationEVOLUTION OF DRUG-ELUTING STENT DRUG ELUTION PROFILE: IS A CRYSTALLINE DRUG FORM THE IDEAL SOLUTION?
EVOLUTION OF DRUG-ELUTING STENT DRUG ELUTION PROFILE: IS A CRYSTALLINE DRUG FORM THE IDEAL SOLUTION? *Giuseppe Sangiorgi, 1 Riccardo Colantonio, 2 Fabio De Luca 3 1. Department of Internal Medicine, Cardiac
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationThe Perfect Drug-Eluting Stent Goals for stent, polymer, and drug development.
The Perfect Drug-Eluting Stent Goals for stent, polymer, and drug development. BY TIM A. FISCHELL, MD, FACC, FSCAI; DWIGHT DISHMON, MD; ADAM ELHADDI, MD; SHADWAN ALSAFWAH, MD; AND SANTHOSH R. MANNEM, MD
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationAffiliation/Financial Relationship
The Next ERA: COMBO Dual Therapy Stent The Unmet Need Roxana Mehran, MD Mount Sinai i School of Medicine i Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationSession: EBC s position on dedicated devices. Pro
Session: EBC s position on dedicated devices Pro Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive Cardiology Dept., Central Hospital of the
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationIntroduction. Original Article
Original Article Clinical performance of a novel ultrathin strut, low-dose, sirolimuseluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention
More informationImpact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 3, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.11.011 CLINICAL RESEARCH
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationStents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.
Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring
More informationEluNIR. Ridaforolimus Eluting Coronary Stent System. Advancing Deliverability for the Road Ahead
Ridaforolimus Eluting Coronary Stent System Advancing Deliverability for the Road Ahead The Coronary Stent System Raising the Bar on Drug-Eluting Stent Technology Introducing the Coronary Stent System,
More information